Cargando…

The role of PD-1 signaling in health and immune-related diseases

Programmed cell death 1 receptor (PD-1) and its ligands constitute an inhibitory pathway to mediate the mechanism of immune tolerance and provide immune homeostasis. Significantly, the binding partners of PD-1 and its associated ligands are diverse, which facilitates immunosuppression in cooperation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Ru-Yue, Zhu, Yun, Shen, Yun-Yan, Xu, Qin-Ying, Tang, Han-Yun, Cui, Ning-Xun, Jiang, Lu, Dai, Xiao-Mei, Chen, Wei-Qing, Lin, Qiang, Li, Xiao-Zhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228652/ https://www.ncbi.nlm.nih.gov/pubmed/37261359 http://dx.doi.org/10.3389/fimmu.2023.1163633

Ejemplares similares

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
por: Tang, Qing, et al.
Publicado: (2022)

Pathological evaluation of renal complications in children following allogeneic hematopoietic stem cell transplantation: a retrospective cohort study
por: Chen, Ru-Yue, et al.
Publicado: (2023)

Based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-PD-1 therapy
por: Xie, Wenjun, et al.
Publicado: (2022)

Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma
por: Zeng, Tian-mei, et al.
Publicado: (2022)

Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1/PD-1 Axis
por: Ruan, Wei-Shuyi, et al.
Publicado: (2020)

Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma
por: Ju, Feng, et al.
Publicado: (2023)

PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study
por: Chen, Shubin, et al.
Publicado: (2022)

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma
por: Zhong, Yu-Min, et al.
Publicado: (2022)

What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
por: Wang, Qingyi, et al.
Publicado: (2021)

Belimumab for Immune-Mediated Necrotizing Myopathy Associated With Anti-SRP Antibodies: A Case Report and Retrospective Review of Patients Treated With Anti-B-Cell Therapy in a Single Center and Literature
por: Cui, Bei-Bei, et al.
Publicado: (2021)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy
por: Wang, Yusha, et al.
Publicado: (2022)

Tr1 Cells as a Key Regulator for Maintaining Immune Homeostasis in Transplantation
por: Song, Yun, et al.
Publicado: (2021)

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
por: Qiao, Xin-wei, et al.
Publicado: (2020)

Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
por: Shen, Jinhai, et al.
Publicado: (2023)

Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy
por: Xu, Yanxin, et al.
Publicado: (2022)

The effect of herbal medicine in innate immunity to Candida albicans
por: Bao, Meng-Yuan, et al.
Publicado: (2023)

Causal effects of the gut microbiome on COVID-19 susceptibility and severity: a two-sample Mendelian randomization study
por: Zhong, Meng-Mei, et al.
Publicado: (2023)

The Integrated Analysis Identifies Three Critical Genes as Novel Diagnostic Biomarkers Involved in Immune Infiltration in Atherosclerosis
por: Ye, Zhen, et al.
Publicado: (2022)

Inhibition of NLRP3 Inflammasome Activation and Pyroptosis in Macrophages by Taraxasterol Is Associated With Its Regulation on mTOR Signaling
por: Yang, Fan, et al.
Publicado: (2021)

Immune-related adverse events correlate with the efficacy of PD-1 inhibitors combination therapy in advanced cholangiocarcinoma patients: A retrospective cohort study
por: Zhang, Yanfang, et al.
Publicado: (2023)

Immune Protection of SIV Challenge by PD-1 Blockade During Vaccination in Rhesus Monkeys
por: Pan, Enxiang, et al.
Publicado: (2018)

Total Glucosides of Paeony Ameliorate Pristane-Induced Lupus Nephritis by Inducing PD-1 ligands(+) Macrophages via Activating IL-4/STAT6/PD-L2 Signaling
por: Liang, Chun-Ling, et al.
Publicado: (2021)

Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma
por: Sun, Peng, et al.
Publicado: (2022)

Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review
por: Qiao, Zi-yun, et al.
Publicado: (2021)

The Regulation and Modification of GSDMD Signaling in Diseases
por: Li, Zihao, et al.
Publicado: (2022)

PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review
por: Liao, Chun-Xu, et al.
Publicado: (2023)

Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer
por: Chen, Qiong-Yuan, et al.
Publicado: (2021)

Epstein–Barr virus-related hemophagocytic lymphohistiocytosis complicated with coronary artery dilation and acute renal injury in a boy with a novel X-linked inhibitor of apoptosis protein (XIAP) variant: a case report
por: Chen, Ru-Yue, et al.
Publicado: (2020)

The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer
por: Zhao, Zihan, et al.
Publicado: (2023)

Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review
por: Liang, Shujing, et al.
Publicado: (2021)

Dietary Aflatoxin B1 attenuates immune function of immune organs in grass carp (Ctenopharyngodon idella) by modulating NF-κB and the TOR signaling pathway
por: He, Xiang-Ning, et al.
Publicado: (2022)

Editorial: Immune Mechanisms in white matter lesions: Clinical and pathophysiological implications
por: Pang, Xiao-Wei, et al.
Publicado: (2023)

Endostatin induces normalization of blood vessels in colorectal cancer and promotes infiltration of CD8+ T cells to improve anti-PD-L1 immunotherapy
por: Chu, Xiao-Dong, et al.
Publicado: (2022)

PRMT5 Inhibition Promotes PD-L1 Expression and Immuno-Resistance in Lung Cancer
por: Hu, Rui, et al.
Publicado: (2022)

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma
por: Hu, Zhang-Wei, et al.
Publicado: (2022)

Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy
por: Lin, Mao, et al.
Publicado: (2022)

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
por: Qin, Weiting, et al.
Publicado: (2019)

ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers
por: Yu, Zheng-Zheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jd0qugdhlspu4qbcj4aa09niuo